Liver Disease and Central Nervous System Dysfunction: Linking the Two - A Narrative Review
DOI:
https://doi.org/10.12775/JEHS.2024.75.56180Keywords
Hepatic encephalopathy, Liver disease, Neuroinflammation, Ammonia toxicity, Gut-liver-brain axisAbstract
Introduction: Liver dysfunction can significantly impact the central nervous system (CNS), leading to neuropsychiatric complications such as hepatic encephalopathy (HE). HE, a potentially reversible condition, results from the accumulation of toxins, particularly ammonia, which a diseased liver fails to detoxify, affecting brain function. It is commonly associated with chronic liver diseases like cirrhosis but can also occur acutely in cases of fulminant liver failure.
Purpose of Research: This review aims to explore the mechanisms linking liver dysfunction to brain impairment in HE and to summarize recent findings on liver disease's effects on CNS dysfunction.
Materials and Methods: The review synthesizes findings from 45 studies on HE pathogenesis and treatment, published between 2003 and 2024. These studies, sourced from PubMed and Scopus, focus on mechanisms including ammonia toxicity, neuroinflammation, oxidative stress, and neurotransmitter imbalance.
Basic Results: HE pathogenesis is multifactorial, with systemic metabolic disturbances causing complex interactions among neurotoxic ammonia buildup, chronic neuroinflammation, oxidative stress, and neurotransmitter imbalances. Traditional therapies like lactulose and rifaximin primarily target ammonia reduction, while newer treatments, including ammonia scavengers, anti-inflammatory agents, and antioxidants, address specific pathogenic pathways. The gut-liver-brain axis, involving gut microbiota's role in CNS functioning, presents promising avenues for adjunctive treatment.
Conclusions: Addressing HE requires a multifaceted approach, including ammonia reduction, inflammation control, and neurotransmitter balance restoration. Traditional therapies remain central to HE management, but emerging treatments and modulation of gut microbiota may enhance outcomes and improve quality of life for patients with liver disease-related brain dysfunction.
References
Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5(Suppl 1)
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ. 2004;328(7447):1046.
Bajaj JS. The modern diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7(8):515-525.
Bajaj JS, Heuman DM, Sanyal AJ, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103(7):1707-1715.
Bajaj JS, Riggio O, Allampati S, et al. Ammonia levels and the severity of hepatic encephalopathy. Am J Gastroenterol. 2013;108(6):881-887.
Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):2014-2021.
Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
Bosoi CR, Rose CF. Oxidative stress: a key player in the pathogenesis of hepatic encephalopathy. J Clin Exp Hepatol. 2013;3(3):169-176.
Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2010;25(1):25-33.
Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int. 2009;29(6):783-788.
Dhiman RK, Saraswat VA, Verma M, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010;25(6):1029-1041.
Elsaid MI, Rustgi VK. Hepatic encephalopathy and the gut-liver-brain axis. Nat Rev Gastroenterol Hepatol. 2020;17(3):138-150.
Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med. 2006;68(4):563-569.
Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2008;48(3):762-764.
Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2014;59(4):1210-1219.
Hadijhambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: novel insights into the pathophysiology and potential therapies. Front Med. 2015;2:40.
Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical and pathophysiological approach. J Gastroenterol Hepatol. 2009;24(8):1479-1486.
Horvath A, Leber B, Schmerboeck B, et al. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on minimal hepatic encephalopathy and intestinal microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2016;44(9):926-935.
Jalan R, McPhail MJ. Albumin: a drug for all seasons in liver disease? J Hepatol. 2012;57(3):896-897.
Jalan R, Shawcross DL, Davies NA. The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol. 2011;43(2):242-247.
Jalan R, Wright G, Davies NA. Liver failure and hepatic encephalopathy. Curr Opin Gastroenterol. 2008;24(3):294-303.
Kale RA, Gupta RK, Saraswat VA, et al. Evaluation of cerebral MR in patients with fulminant hepatic failure. J Hepatol. 2014;60(3):471-478.
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on Acute Liver Failure. Hepatology. 2012;55(3):965-967.
Montagnese S, Bajaj JS. Impact of hepatic encephalopathy in cirrhosis on quality of life: a decade later. J Clin Gastroenterol. 2015;49(Suppl 1)
Norenberg MD, Rao KV. Astrocyte swelling in hepatic encephalopathy: role of glutamine and aquaporin-4. J Hepatol. 2008;48(3):314-319.
Qu C, Chen K, Xie Y, Zhao H, Wang J. Manganese deposition in brain and hepatic encephalopathy: an MR imaging study. Radiology. 2015;275(2):478-485.
Reverter E, Tandon P, Bastiampillai R, et al. Diagnosis and management of acute-on-chronic liver failure. Clin Liver Dis. 2021;25(1):65-82.
Riggio O, Pasquale C, Ridola L, et al. Drugs for the treatment of hepatic encephalopathy: a review. Am J Gastroenterol. 2010;105(5):1136-1142.
Romero-Gomez M, Cordoba J, Jover R, et al. Normalizing amino acid balance reduces hepatic encephalopathy: results of a multicenter, randomized, controlled trial. J Hepatol. 2009;50(5):932-939.
Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2008;48(2):355-362.
Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation in cirrhosis: a potential trigger for the development of hepatic encephalopathy. Gastroenterology. 2011;140(2):488-497.
Swain MG, Jones DE. Fatigue in chronic liver disease: new insights and therapeutic approaches. Liver Int. 2012;32(9):1211-1219.
Tapper EB, Jiang ZG, Patwardhan VR. Refining the diagnosis and management of hepatic encephalopathy: results of a national survey. Gastroenterology. 2015;148(7):220-229.
Vaquero J, Polson J, Chung C, et al. Improving the outcome of patients with acute liver failure: the impact of early liver transplantation and transplantation of the "acute liver failure" graft. Liver Transpl. 2003;9(9):879-889.
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735.
Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2009;51(2):368-373.
Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21(1):95-110.
Wright G, Noiret L, Olde Damink SW, Jalan R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 2011;31(2):163-175.
Zhang Y, Wang J, Zhang T, et al. Diffusion tensor imaging reveals white matter microstructural changes in hepatic encephalopathy. J Neuroimaging. 2012;22(1):63-68.
Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: implications for hepatic coma. J Pharmacol Exp Ther. 2009;128(1):175-179.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maciej Tenderenda, Bartosz Buczkowski, Piotr Oleksy, Agnieszka Klecza, Aleksandra Broniak, Magdalena Reclik, Karol Zieliński, Aarushi Chourasia, Krzysztof Nowakowski, Martyna Chraścina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 76
Number of citations: 0